<DOC>
	<DOC>NCT01908322</DOC>
	<brief_summary>The study aims to investigate patient characteristics of intermediate stage hepatocellular carcinoma patients treated with Nexavar and their distribution to different treatment groups as well as determining efficacy and safety parameters.</brief_summary>
	<brief_title>Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Patients with a diagnosis of unresectable intermediate stage hepatocellular carcinoma (BCLCB) for whom the decision has been taken by the investigator to prescribe Nexavar (the BCLC intermediate stage (BCLCB) consists of ChildPugh A and B patients with large/multifocal HCC who do not have cancer related symptoms, macrovascular invasion or extrahepatic spread). Prior targeted therapy for hepatocellular carcinoma.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>Intermediate stage</keyword>
	<keyword>Observational study</keyword>
</DOC>